中国组织工程研究 ›› 2021, Vol. 25 ›› Issue (19): 3016-3023.doi: 10.3969/j.issn.2095-4344.3523

• 干细胞培养与分化 stem cell culture and differentiation • 上一篇    下一篇

中药复方制剂抑制CD133+肝癌干细胞增殖及干性转录因子的表达

覃艳春1,荣  震2,蒋锐沅1,付  彬1,洪晓华1,莫春梅2   

  1. 1广西中医药大学研究生学院,广西壮族自治区南宁市  530000;2广西中医药大学第一附属医院,广西壮族自治区南宁市  530000
  • 收稿日期:2020-05-11 修回日期:2020-05-15 接受日期:2020-06-29 出版日期:2021-07-09 发布日期:2021-01-13
  • 通讯作者: 莫春梅,主任医师,广西中医药大学第一附属医院,广西壮族自治区南宁市 530000
  • 作者简介:莫春梅,主任医师,广西中医药大学第一附属医院,广西壮族自治区南宁市 530000
  • 基金资助:
    国家自然科学基金(81760850),项目负责人:莫春梅;广西高校中青年教师基础能力提升项目(2018KY0282),项目负责人:莫春梅;广西医疗卫生适宜技术开发与推广应用项目(S2018046),项目负责人:莫春梅;广西中医药大学第一附属医院院内制剂研究与开发(2018ZJ004),项目负责人:莫春梅

Chinese medicine compound preparation inhibits proliferation of CD133+ liver cancer stem cells and the expression of stemness transcription factors

Qin Yanchun1, Rong Zhen2, Jiang Ruiyuan1, Fu Bin1, Hong Xiaohua1, Mo Chunmei2   

  1. 1Department of Graduate, Guangxi University of Chinese Medicine, Nanning 530000, Guangxi Zhuang Autonomous Region, China; 2First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530000, Guangxi Zhuang Autonomous Region, China
  • Received:2020-05-11 Revised:2020-05-15 Accepted:2020-06-29 Online:2021-07-09 Published:2021-01-13
  • Contact: Mo Chunmei, Chief physician, First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530000, Guangxi Zhuang Autonomous Region, China
  • About author:Qin Yanchun, Master candidate, Department of Graduate, Guangxi University of Chinese Medicine, Nanning 530000, Guangxi Zhuang Autonomous Region, China
  • Supported by:
    the National Natural Science Foundation of China, No. 81760850 (to MCM); the Basic Ability Improvement Project of Young and Middle-Aged Teachers in Guangxi Universities, No. 2018KY0282 (to MCM); the Guangxi Medical and Health Appropriate Technology Development and Application Project, No. S2018046 (to MCM); the Research and Development of Hospital Preparations in the First Affiliated Hospital of Guangxi University of Chinese Medicine, No. 2018ZJ004 (to MCM)

摘要:

文题释义:
肿瘤干细胞:是存在于肿瘤组织中,具有无限自我更新能力并能产生异质性肿瘤细胞群的极少数细胞。肿瘤干细胞在肿瘤的形成和生长过程中发挥决定性作用,是肿瘤复发和转移的根源。
CD133:CD133在许多肿瘤中相继被报道,目前已经是一个非常有价值的分选肿瘤干细胞的标志物,研究发现CD133+肿瘤细胞与肿瘤发生、侵袭、转移、耐药及复发有着密切的关系,因此深入了解CD133+肿瘤细胞的分子生物学特性对寻求有效的抗癌治疗,特别是靶向肿瘤干细胞的治疗是相当必要的。

背景:癌症起源于干细胞的恶性转化越来越得到普遍认同。肝癌干细胞具有不断自我更新与多向分化潜能,可促进肝癌的发生发展、术后复发和耐药性的产生。
目的:探讨中药复方制剂敷和备化方对CD133+肝癌干细胞增殖及干性转录因子表达的影响。
方法:采用免疫磁珠法分选出CD133+HepG2肝癌干细胞,分别用2%,4%,8%,10%,12%,16% 6个不同体积分数中药复方制剂敷和备化方含药血清干预CD133+HepG2肝癌干细胞,通过CCK-8法检测细胞增殖抑制作用,筛选出最佳体积分数含药血清。然后将CD133+HepG2肝癌干细胞分为二甲基亚砜组、敷和备化方组、血清对照组、空白对照组,其中二甲基亚砜组用0.05%二甲基亚砜干预,敷和备化方组用体积分数为16%敷和备化方含药血清干预,血清对照组用体积分数为16%正常大鼠血清干预,干预6 d后采用流式细胞术检测CD133+HepG2肝癌干细胞百分比,RT-PCR以及Western blot检测干细胞转录因子SOX2、NANOG和OCT4的mRNA以及蛋白表达。
结果与结论:①中药复方制剂敷和备化方含药血清对CD133+HepG2细胞增殖有抑制作用,且与时间、体积分数相关,其中体积分数为16%敷和备化方含药血清干预72 h抑制作用最明显(P < 0.05);②与血清对照组和空白对照组相比,敷和备化方组和二甲基亚砜组都可降低CD133+HepG2细胞百分比(P < 0.05),且敷和备化方组作用更明显;③与空白对照组和血清对照组相比,敷和备化方组和二甲基亚砜组都可下调干细胞转录因子 SOX2、NANOG、OCT4 mRNA和蛋白表达(P < 0.05),且敷和备化方组作用更明显;④结果表明,中药复方制剂敷和备化方含药血清能有效降低肝癌干细胞表面标记物 CD133和干细胞转录因子SOX2、NANOG、OCT4的表达水平,降低肝癌干细胞恶性程度。
https://orcid.org/0000-0003-3229-5838(覃艳春) 

中国组织工程研究杂志出版内容重点:干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程

关键词: 干细胞, 肝癌干细胞, 敷和备化方, 含药血清, CD133, 干细胞转录因子

Abstract: BACKGROUND: The malignant transformation of cancer originating from stem cells is increasingly recognized. Liver cancer stem cells have the potential of continuous self-renewal and multi-directional differentiation, which can promote the occurrence and development of liver cancer, postoperative recurrence and the production of drug resistance.
OBJECTIVE: To explore the effect of Fuhe preparation formula on proliferation of CD133+ liver cancer stem cells and stemness transcription factor expression. 
METHODS:  CD133+ HepG2 liver cancer stem cells were selected by immunomagnetic bead method. CD133+ HepG2 cells were treated with serum containing 2%, 4%, 8%, 10%, 12% and 16% Fuhe preparation formula respectively. The inhibitory rate of CD133+ HepG2 cells was determined by CCK-8 method, and the optimal volume fraction of serum containing drugs was selected. The CD133+ HepG2 liver cancer stem cells were divided into dimethyl sulfoxide group, application and preparation group, serum control group and blank control group. Cells in the dimethyl sulfoxide group were intervened with 0.05% dimethyl sulfoxide. Cells in the application and preparation group were intervened with 16% application and preparation containing serum. Cells in the serum control group were intervened with 16% normal rat serum. After 6 days of intervention, the percentage of CD133+ HepG2 liver cancer stem cells was detected by flow cytometry. The mRNA and protein levels of transcription factors SOX2, NANOG, and OCT4 were detected by RT-PCR and western blot assay. 
RESULTS AND CONCLUSION: (1) The serum containing application and preparation formula inhibited the proliferation of CD133+ HepG2 cells, which was related to the time and concentration. The inhibitory effect of 16% application and preparation formula was the most obvious in 72 hours (P < 0.05). (2) Compared with the serum control and blank control groups, the percentage of CD133+ HepG2 liver cancer stem cells was decreased in the application and preparation and dimethyl sulfoxide groups (P < 0.05), and the effect was more obvious in the application and preparation group. (3) Compared with the serum control and blank control groups, SOX2, NANOG, OCT4 mRNA and protein expression levels were downregulated in the application and preparation and dimethyl sulfoxide groups (P < 0.05), and the effect was more obvious in the application and preparation group. (4) These findings conclude that the serum containing application and preparation formula can effectively reduce the expression levels of CD133, a marker on the surface of liver cancer stem cells, and transcription factors SOX2, NANOG and OCT4, and can reduce the malignant degree of liver cancer stem cells. 

Key words: stem cells, liver cancer stem cells, application and preparation formula, drug serum, stem cell transcription factors

中图分类号: